Epithelial–mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib

Hu, Wentao; Pei, Hailong; Sun, Fei; Li, Pengfei; Nie, Jing; Li, Bingyan; Hei, Tom K.; Zhou, Guangming

doi:10.1093/jrr/rry050

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSAIDs are non-hormonal compounds that are commonly used as symptomatic treatment for dysmenorrhea and heavy bleeding associated with adenomyosis (10,11). Findings from recent studies have suggested that NSAIDs are also capable of inhibiting angiogenesis, proliferation, the expression of aromatase P450 and epithelial-mesenchymal transition (EMT) in numerous cancer models, such as colorectal cancer, prostate cancer and human glioblastoma endothelial cells, highlighting their potentially novel properties (12)(13)(14). Additionally, the long-term use of NSAIDs has been proposed as a therapeutic Celecoxib, a selective COX-2 inhibitor, markedly reduced the severity of tamoxifen-induced adenomyosis in a murine model strategy for a number of malignancies, including prostate, colon and breast cancer (15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

Celecoxib, a selective COX‑2 inhibitor, markedly reduced the severity of tamoxifen‑induced adenomyosis in a murine model

Jin

Liu

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

The aim of the present study was to evaluate the effects of the selective cyclooxygenase (COX)-2 inhibitor celecoxib on the development of uterine adenomyosis in mice. ICR neonatal mice were first exposed to tamoxifen to establish a mouse model of adenomyosis. Following 60 days of celecoxib treatment, pathological formation of adenomyosis lesions and the depth of myometrial infiltration were evaluated using hematoxylin and eosin staining. To examine thermal pain modulation in mice, a hotplate test was conducted every 15 days from postnatal day 30 onwards. Immunohistochemistry was performed to assess the expression of aromatase P450, N-cadherin, E-cadherin, COX-2 and cluster of differentiation 31, whereas the levels of estrogen were analyzed in uterine tissue homogenates using ELISA. Masson trichrome staining was performed to assess the extent of fibrosis in the uterus. Celecoxib treatment significantly inhibited the depth of infiltration into the myometrium, resulting in significantly reduced disease severity. Treatment with high doses of celecoxib significantly prolonged thermal response latency. Following celecoxib treatment, the expression of E-cadherin was significantly increased whereas the expression of N-cadherin was significantly decreased. Concomitantly, the extent of fibrosis was also reduced following celecoxib treatment. Uterine tissue homogenates isolated from mice treated with both high and low doses of celecoxib exhibited lower concentrations of estrogen and decreased expression of aromatase P450. These observations suggest that celecoxib reduces adenomyosis severity by suppressing estrogen production in the uterus, reversing epithelial-mesenchymal transition and relieving fibrosis. Taken together, the results of the present study support the potential use of celecoxib, a selective COX-2 inhibitor, for the treatment of adenomyosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Celecoxib, a selective COX‑2 inhibitor, markedly reduced the severity of tamoxifen‑induced adenomyosis in a murine model

Jin

Liu

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Epithelial-mesenchymal transition (EMT) is an important process to transform epithelial cells into mesenchymal cells, which is involved in tumorigenesis, invasion and metastasis [ 44 , 45 ]. In the process of EMT, the epithelial marker E-cadherin is downregulated, while the mesenchymal markers N-cadherin, fibronectin, and vimentin are upregulated significantly [ 46 ].…”

Section: Resultsmentioning

confidence: 99%

Semiconducting polymer nano-radiopharmaceutical for combined radio-photothermal therapy of pancreatic tumor

Shi

Zhang

et al. 2021

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Background Pancreatic ductal adenocarcinoma (PDAC) is a devastatingly malignant tumor with a high mortality. However, current strategies to treat PDAC generally have low efficacy and high side-effects, therefore, effective treatment against PDAC remains an urgent need. Results We report a semiconducting polymer nano-radiopharmaceutical with intrinsic photothermal capability and labeling with therapeutic radioisotope 177Lu (177Lu-SPN-GIP) for combined radio- and photothermal therapy of pancreatic tumor. 177Lu-SPN-GIP endowed good stability at physiological conditions, high cell uptake, and long retention time in tumor site. By virtue of combined radiotherapy (RT) and photothermal therapy (PTT), 177Lu-SPN-GIP exhibited enhanced therapeutic capability to kill cancer cells and xenograft tumor in living mice compared with RT or PTT alone. More importantly, 177Lu-SPN-GIP could suppress the growth of the tumor stem cells and reverse epithelial mesenchymal transition (EMT), which may greatly reduce the occurrence of metastasis. Conclusion Such strategy we developed could improve therapeutic outcomes over traditional RT as it is able to ablate tumor with relatively lower doses of radiopharmaceuticals to reduce its side effects. Graphical abstract

show abstract

“…Epithelial-mesenchymal transition (EMT) is an important process to transform epithelial cells into mesenchymal cells, which is involved in tumorigenesis, invasion and metastasis [42,43]. In the process of EMT, the epithelial marker E-cadherin is downregulated, while the mesenchymal markers N-cadherin, bronectin, and vimentin are upregulated signi cantly [44].…”

Section: Mechanistic Study On Therapeutic Effectmentioning

confidence: 99%

Semiconducting Polymer Nano-Radiopharmaceutical For Combined Radio-Photothermal Therapy of Pancreatic Tumor

Shi¹,

Li²,

Zhang³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma (PDAC) is a devastatingly malignant tumor with a high mortality. However, current strategies to treat PDAC generally have low efficacy and high side-effects, therefore, effective treatment against PDAC remains an urgent need. Results: We report a semiconducting polymer nano-radiopharmaceutical with intrinsic photothermal capability and labeling with therapeutic radioisotope 177Lu (177Lu-SPN-GIP) for combined radio- and photothermal therapy of pancreatic tumor. 177Lu-SPN-GIP endowed good stability at physiological conditions, high cell uptake, and long retention time in tumor site. By virtue of combined radiotherapy (RT) and photothermal therapy (PTT), 177Lu-SPN-GIP exhibited enhanced therapeutic capability to kill cancer cells and xenograft tumor in living mice compared with RT or PTT alone. More importantly, 177Lu-SPN-GIP could suppress the growth of the tumor stem cells and reverse epithelial mesenchymal transition (EMT), which may greatly reduce the occurrence of metastasis. Conclusion: Such strategy we developed could improve therapeutic outcomes over traditional RT as it is able to ablate tumor with relatively lower doses of radiopharmaceuticals to reduce its side effects.

show abstract

Epithelial–mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib

Cited by 5 publications

References 28 publications

Celecoxib, a selective COX‑2 inhibitor, markedly reduced the severity of tamoxifen‑induced adenomyosis in a murine model

Celecoxib, a selective COX‑2 inhibitor, markedly reduced the severity of tamoxifen‑induced adenomyosis in a murine model

Semiconducting polymer nano-radiopharmaceutical for combined radio-photothermal therapy of pancreatic tumor

Semiconducting Polymer Nano-Radiopharmaceutical For Combined Radio-Photothermal Therapy of Pancreatic Tumor

Contact Info

Product

Resources

About